COVID-19 vaccine reaches phase-2 trials in China
Share - WeChat

BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- Youth trace roots by sharing stories
- Food delivery platforms to do away with financial penalties, sparking debate
- Data show rising labor, business disputes
- Bocholt group visits Wuxi to honor friendship
- Domestic tourism sees major jump in visitors and spending
- Vibrant autumn colors attract tourists to Changchun park